Company / R&D per Share
Theravance Biopharma, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.76
FY2025
5-year range
$0.62 / $3.51
FY2021-FY2025
Trend
-3.4%
vs FY2024
Sector context
#157 of 208
Health Care
What the data says
Theravance Biopharma, Inc.'s r&d per share of $0.76 is lower than 75% of companies in the Health Care sector (FY2025). R&D per Share has fluctuated over the past 10 years, ranging from $0.62 in FY2023 to $4.58 in FY2020.
Based on SEC 10-K filings.
0.76 in FY2025 with a 5-year CAGR of -30.2%.
Improved from $0.62 to $0.76 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -40.0%
- 5-Year CAGR
- -30.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 208This company $0.76 Sector average $28.82
▼
-97.4% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 3.4% year-over-year.
- Ranks #157 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
- Lowest r&d per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.76 | -3.4% |
| FY2024 | $0.78 | +25.7% |
| FY2023 | $0.62 | -82.2% |
| FY2022 | $3.51 | +16.5% |
| FY2021 | $3.01 | -34.2% |
| FY2020 | $4.58 | +46.6% |
| FY2019 | $3.12 | +19.8% |
| FY2018 | $2.61 | -20.8% |
| FY2017 | $3.29 | -11.8% |
| FY2016 | $3.73 | -0.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026